PMID- 20628810
OWN - NLM
STAT- MEDLINE
DCOM- 20110628
LR  - 20151119
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 125
IP  - 2
DP  - 2011 Jan
TI  - HER2 status in a population-derived breast cancer cohort: discordances during 
      tumor progression.
PG  - 553-61
LID - 10.1007/s10549-010-1029-2 [doi]
AB  - This retrospective study investigates the correlation of intra-individual HER2 
      status between primary breast cancers and corresponding recurrences in a 
      population derived cohort. The REMARK criteria were used as reference. In 151 
      breast cancer patients, primary tumors were analyzed for HER2 status on 
      histopathology sections using immunohistochemistry (IHC) confirmed by 
      fluorescence in situ hybridization (FISH) for IHC 2+ and 3+. Recurrences (loco 
      regional and distant) were investigated by aspiration cytology, using HER2 
      immunocytochemistry (ICC) or FISH (ICC in 84 patients and FISH in 102 patients). 
      In the 151 patients, sites of recurrence were bone/bone marrow 30%, liver 16%, 
      local recurrence 18%, lung/pleura 10%, axillary lymph nodes 9%, skin (non-local) 
      7%, supra clavicular lymph nodes 5%, and other sites 7%. In 15 patients (10%) 
      HER2 status changed, 7 of 108 patients (6%) from HER2 negative to HER2 positive 
      and 8 of 43 (19%) from HER2 positive to HER2 negative. Intra-patient agreement in 
      HER2 status was 76% (95% CI 64-87%), and the disagreement was 10% (95% CI 5-15%). 
      The multivariable Cox analysis showed a significantly increased risk of dying in 
      the patient group with changed HER2 status compared to patients with concordant 
      positive HER2 status. Overall survival HR is 5.47 (95% CI 2.01-14.91) and 
      survival from relapse HR is 3.22 (95% CI 1.18-8.77). The unstable status for HER2 
      in breast cancer is clinically significant and should motivate more frequent 
      testing of recurrences.
FAU - Wilking, Ulla
AU  - Wilking U
AD  - Department of Oncology-Pathology, Karolinska Institutet & Cancer Center 
      Karolinska, Stockholm, Sweden. ulla.wilking@telia.com
FAU - Karlsson, Eva
AU  - Karlsson E
FAU - Skoog, Lambert
AU  - Skoog L
FAU - Hatschek, Thomas
AU  - Hatschek T
FAU - Lidbrink, Elisabet
AU  - Lidbrink E
FAU - Elmberger, Goran
AU  - Elmberger G
FAU - Johansson, Hemming
AU  - Johansson H
FAU - Lindstrom, Linda
AU  - Lindstrom L
FAU - Bergh, Jonas
AU  - Bergh J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100714
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers, Tumor/analysis
MH  - Breast Neoplasms/*chemistry/mortality/pathology/secondary
MH  - Cell Proliferation
MH  - Disease Progression
MH  - Female
MH  - Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - *Neoplasm Recurrence, Local
MH  - Neoplasms, Second Primary/*chemistry/pathology
MH  - Receptor, ErbB-2/*analysis
MH  - Retrospective Studies
MH  - Trastuzumab
EDAT- 2010/07/16 06:00
MHDA- 2011/06/29 06:00
CRDT- 2010/07/15 06:00
PHST- 2010/02/09 00:00 [received]
PHST- 2010/06/30 00:00 [accepted]
PHST- 2010/07/15 06:00 [entrez]
PHST- 2010/07/16 06:00 [pubmed]
PHST- 2011/06/29 06:00 [medline]
AID - 10.1007/s10549-010-1029-2 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2011 Jan;125(2):553-61. doi: 10.1007/s10549-010-1029-2. 
      Epub 2010 Jul 14.